Sante Capital Fund’s 10x Genomics TXG Stock Holding History

Sante Capital Fund’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,522	Closed	-$690K	–	109
2021 Q2	$690K	Buy	+3,522	New	+$637K	0.28%	90

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sante Capital Fund's TXG Position: Q3 2021 in Review

Sante Capital Fund sold out of 10x Genomics (TXG) in Q3 2021, closing a stake of 3,522 shares — an estimated $690K sold.

Sante Capital Fund first reported a position in TXG in Q2 2021 and held it in 1 quarter. The position peaked at $690K in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

Sante Capital Fund reported no remaining 10x Genomics position as of Q3 2021 after selling out during the quarter.
Sante Capital Fund sold 3,522 10x Genomics shares in Q3 2021, an estimated $690K.
Sante Capital Fund first reported a position in 10x Genomics in Q2 2021 and held it in 1 quarter.
Sante Capital Fund's 10x Genomics position peaked at $690K in Q2 2021.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on Sante Capital Fund's 13F filing for Q3 2021, filed 15 Nov 2021.